Analyst Ratings February 11, 2026

RBC Raises DuPont Price Target to $161, Cites Momentum Amid Note Irregularities

Analysts boost valuation as DuPont posts Q4 2025 beats; RBC’s note contains a possible data mix-up referencing another company

By Jordan Park DD
RBC Raises DuPont Price Target to $161, Cites Momentum Amid Note Irregularities
DD

RBC Capital raised its price target on DuPont to $161 from $150 while keeping an Outperform rating. The chemical maker has delivered strong recent price performance and reported Q4 2025 results that topped expectations. The RBC research note, however, appears to include details that pertain to another company, introducing an unusual caveat to the upgrade.

Key Points

  • RBC Capital raised DuPont’s price target to $161 from $150 and maintained an Outperform rating - impacts the chemicals and industrials sectors and investor sentiment in equity markets.
  • DuPont’s market performance shows a 70.84% return over six months and a 22.96% YTD gain; company trades at a P/E of 27.16 and a 7% free cash flow yield - relevant to valuation analysts and institutional investors.
  • DuPont beat Q4 2025 estimates with EPS of $0.46 versus $0.43 expected and revenue of $1.7 billion versus $1.69 billion forecast; KeyBanc also raised its target to $57 after portfolio changes - pertinent to earnings and corporate strategy observers.

RBC Capital has increased its price target on DuPont (NYSE: DD) to $161.00 from $150.00 and left its rating at Outperform, reflecting a 7.3% lift in the firm's valuation for the chemicals company.

Market performance has been robust: InvestingPro data quoted by RBC shows DuPont producing a 70.84% total return over the last six months and a 22.96% gain year-to-date. The company is trading at a price-to-earnings ratio of 27.16 and carries a free cash flow yield of 7%, metrics the note presents as evidence of solid cash-generation potential.

Notably, the RBC analyst report contains an apparent content anomaly. Portions of the note read as if they describe a different technology-oriented firm - Datadog - rather than DuPont. The commentary that appears misattributed refers to three consecutive quarters of accelerating growth and cites calendar year 2026 guidance that "came in better than feared." The same section states that the analyst team will keep their Outperform rating with "higher conviction" ahead of an analyst day scheduled for Thursday. The inclusion of these lines introduces uncertainty about whether some phrasing was carried over in error.

On the fundamentals, DuPont reported fourth-quarter 2025 results that exceeded analyst expectations. The company posted earnings per share of $0.46 versus the expected $0.43 and generated revenue of $1.7 billion compared with forecasts of $1.69 billion. Those beats are highlighted in the research commentary as evidence of DuPont’s ability to outperform near-term estimates.

Separately, KeyBanc has also adjusted its view on DuPont. The firm raised its price target from $51 to $57 and retained an Overweight rating. KeyBanc analyst Aleksey Yefremov cited increased confidence in DuPont’s long-term growth after the company’s portfolio changes following the Qnity divestiture.

Taken together, the analyst moves and the quarterly beats are presented as reinforcing a broadly positive tone among Wall Street observers. At the same time, the RBC note’s apparent reference to another company highlights a clear editorial inconsistency within the published research.


Summary: RBC Capital lifted its DuPont price target to $161 and kept an Outperform rating amid strong recent stock returns and Q4 2025 results that topped expectations. The RBC research brief appears to contain text about Datadog, raising questions about the note’s accuracy in parts. KeyBanc also raised its target and maintained an Overweight view after portfolio restructuring.

Risks

  • The RBC research note includes language that appears to reference Datadog rather than DuPont, indicating a possible content or attribution error in published analyst commentary - this affects investor reliance on research notes in equity markets.
  • References to CY/26 guidance that "came in better than feared" and the analyst day mention reflect ongoing guidance and event-driven uncertainty, which can influence short-term stock volatility in the chemicals sector.
  • KeyBanc’s increased confidence is tied to DuPont’s portfolio restructuring after the Qnity divestiture; the longer-term benefits of such strategic moves remain an uncertainty for long-term growth projections and valuations.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026